Personalis, Inc. (NASDAQ:PSNL) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET

Company Participants

Chris Hall - Chief Executive Officer and President
Aaron Tachibana - Chief Financial and Chief Operating Officer
Rich Chen - Chief Medical Officer and Executive Vice President, R&D

Conference Call Participants

Madison Pasterchick - Morgan Stanley
Vidyun Bais - BTIG
Dan Brennan - TD Cowen
Thomas Flaten - Lake Street
Mike Mattson - Needham
Arthur He - H.C. Wainwright

Operator

Good day and welcome to the Personalis First Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Mr. Aaron Tachibana. Please go ahead.

Aaron Tachibana

Thank you, operator. Welcome to Personalis’ first quarter 2024 earnings call. Joining today’s call are Chris Hall, Chief Executive Officer and President and I am Aaron Tachibana, Chief Financial and Chief Operating Officer and Rich Chen, Chief Medical Officer and EVP of R&D.

All statements made on this call that do not relate to matters of historical facts should be considered forward-looking statements within the meaning of U.S. securities laws. For example, any statements regarding trends and expectations for our financial performance this year and longer term, cash runway, revenue expectations and timing, reimbursement goals, size and booking of orders, products, services, technology, clinical milestones, the outcome and timing of reimbursement decisions, expectations for our existing and future collaboration activities, cost expectations, our market opportunity and business outlook. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. We encourage you to review our most recent filings with the SEC, including the risk factors described in our most recent filings. Personalis undertakes no obligation to update these statements, except as required by applicable law.

Our press release with our first quarter 2024 results is available on our website www.personalis.com under the Investors section and includes additional details about our financial results. Our website also has our latest SEC filings, which we encourage you to review. A recording of today’s call will be available on our website by 5 p.m. Pacific Time today.

Now, I would like to turn the call over to Chris for his comments and first quarter business highlights.

Chris Hall

Thank you, Aaron. Good afternoon, everyone and thank you for joining us. I am very proud of our team at Personalis as we continue to fight cancer with our novel technologies. For those of you joining one of our calls for the first time, welcome. Personalis is one of the leaders in the fast growing MRD testing market. MRD stands for minimal residual disease. With our first of its kind ultra-sensitive MRD test, we are able to spot cancer when it’s only one fragment of tumor DNA circulating in a million DNA fragments in the blood. Our technologies are used by many of the world’s top biopharma companies to improve clinical trial results by new ways to personalize treatment and power a new generation of more effective therapies.